{"pub": "axios", "url": "https://axios.com/windfalls-of-secrecy-express-scripts-0cb9440d-08b5-4702-a33c-cfe2fb93422b.html", "downloaded_at": "2019-10-08 10:00:00.866402+00:00", "title": "The windfalls of secrecy", "language": "en", "text": "Express Scripts met with analysts at banking giant Barclays in March and mentioned how its \"industry-leading EBITDA per claim\" \u2014 a measure of profit they collect on each prescription \u2014 likely will be \"sustainable over time,\" according to Barclays' note to Wall Street. Those comments come as each of the big three pharmacy benefit managers are being attached to health insurers.\n\nThe big picture: Some PBMs use a different \"transparent\" model to earn money, but they are in the minority. New documents obtained by Axios peel back the curtain on the traditional drug benefits business, though many details remain hidden from public view.", "description": "New documents reveal how PBMs work and make money.", "authors": [], "top_image": "https://images.axios.com/oo4f9Zb48BMugDyka6e2CCMovkM=/0x0:1920x1080/1920x1080/2018/03/29/1522362193865.png", "published_at": "2018-03-30"}